Dapsone-Induced Schistocytosis and Hemolysis in Adult Patients, 2005-2021

19 adult patients receiving dapsone at a French university hospital were studied for hemolytic effects. 10 patients (52.6%) exhibited detectable schistocytes, with levels ranging from 2 to 44 per 1000 erythrocytes. This retrospective observational dataset by Alexis Archambeaud, last updated in 2026, likely contains laboratory findings comparing hematological markers between schistocyte-positive and negative groups.

Use Cases

• Correlating schistocyte presence with hemoglobin decrease based on reported average drops of -2.7 g/dL vs -1.6 g/dL.
• Analyzing the relationship between dapsone use and elevated LDH levels based on reported medians of 557 U/L vs 273 U/L.
• Studying the time course of schistocytosis regression based on the reported 3-18 day window after treatment discontinuation.
• Investigating associations between methemoglobinemia and schistocytosis based on reported levels of 5.2% vs 1.9%.

Strengths

• Data covers a 16-year period (2005-2021) from a single institution, providing longitudinal consistency.
• Includes specific quantitative results for key hematological markers like schistocyte count, hemoglobin, and LDH.
• Released under a permissive CC-BY-4.0 license, allowing for broad reuse and redistribution.

Limitations

• Row count is unknown, which may limit suitability assessment for statistical modeling.
• Column-level documentation is absent; field semantics must be inferred after download.
• The sample size is explicitly noted as small (19 patients), limiting statistical power.

Provenance

Source

University Hospital of Tours, France.

Collection Method

Single-centre retrospective observational study; data extracted from electronic medical records.

Time Range

2005–2021

Freshness

Last updated 2026-05-22 17:42:23; freshness should be verified.

Geography

Tours, France.